MACK Merrimack Pharmaceuticals, Inc.

3.16
+0  (0%)
Previous Close 3.16
Open 3.17
Price To book 0.00
Market Cap 412.60M
Shares 130,570,000
Volume 1,124,050
Short Ratio 13.80
Av. Daily Volume 2,009,520

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2018.
MM-141
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
MM-302 HERMIONE
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
ONIVYDE
Cancer - second line pancreatic
Phase 2 initiated mid Feb 2015. Data due by end of 2018.
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
ONIVYDE
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
ONIVYDE
Cancer - front line pancreatic

Latest News

  1. Merrimack Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MACK) : April 19, 2017
  2. Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : April 18, 2017
  3. Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research
  4. Merrimack Declares $140M Special Dividend in Connection with Recently Completed Asset Sale
  5. Merrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 and MM-310
  6. Are Options Traders Betting on a Big Move in Merrimack (MACK) Stock?
  7. Merrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion
  8. Merrimack to Present at the 2017 American Association for Cancer Research Annual Meeting
  9. Merrimack (MACK) Starts Enrollment in Solid Tumors Study
  10. ​Merrimack asset sale prompts legal blowback
  11. Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors
  12. Lawyer: former Merrimack employee accused of insider trading to fight charges
  13. Merrimack Pharmaceuticals, Inc. :MACK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
  14. Biotech's Fall as President Trump to Address Pricing Concerns: Today's Research Reports on Arena Pharmaceuticals and Merrimack Pharmaceuticals
  15. Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top
  16. These 5 Stocks Under $10 Could Explode Up Soon
  17. Edited Transcript of MACK earnings conference call or presentation 1-Mar-17 1:30pm GMT
  18. Merrimack's (MACK) Q4 Loss In-Line With Estimates
  19. Merrimack reports 4Q loss